dm+d
18548003
Articles
Example medicines to prescribe by brand name in primary care
27 March 2022
Prescribe certain medicines by brand to ensure supply of the same product. Examples are grouped by therapeutic area. The list of products is not exhaustive. Extended-release methylphenidate: A review of the pharmacokinetic profiles of available products
23 December 2020
This review discusses current NICE recommendations for the use of methylphenidate for the treatment of ADHD and describes the pharmacokinetic differences between the currently available…Safety in Lactation: Drugs for ADHD
21 October 2020
Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. The use of drugs for attention…Medicine Compliance Aid Stability
Medikinet XL
Flynn Pharma Ltd
Flynn Pharma Ltd
Medikinet XL
Capsules m/r 5mg, 10mg, 20mg, 30mg, 40mg
R2 · Red 2 Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Protect from light. Protect from moisture.
1 February 2015
Ritalin
Novartis Pharmaceuticals UK Ltd
Novartis Pharmaceuticals UK Ltd
Ritalin
Tablets 10mg
A2 · Amber 2 No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special requirements for storage.
1 February 2015
Medikinet
Flynn Pharma Ltd
Flynn Pharma Ltd
Medikinet
Tablets 5mg, 10mg, 20mg
R2 · Red 2 Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Protect from light. Protect from moisture.
1 February 2015
Concerta XL
Janssen-Cilag Ltd
Janssen-Cilag Ltd
Concerta XL
Tablets m/r 18mg, 27mg, 36mg
R1 · Red 1 Stability data indicates that the drug is not suitable for CAs.
Unsuitable
Not suitable for compliance aid - packaged with a desiccant.
1 February 2015
Equasym XL
Shire Pharmaceuticals Ltd
Shire Pharmaceuticals Ltd
Equasym XL
Capsules m/r 10mg, 20mg, 30mg
A2 · Amber 2 No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special requirements for storage.
1 February 2015
Matoride XL
Sandoz Ltd
Sandoz Ltd
Matoride XL
Tablets prolonged release f/c 36mg, 54mg
R2 · Red 2 Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Drying plug in bottle, protect from moisture.
30 October 2015
Lactation Safety Information
-
Limited published evidence of safety
Negligible amounts in breast milk
Monitor infant for decreased appetite/weight gain, sleep disturbances, irritability
28 June 2021